IPP Bureau

Briefs: Piramal Enterprises and Shilpa Medicare
Briefs: Piramal Enterprises and Shilpa Medicare

By IPP Bureau - December 02, 2022

Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval

Freudenberg Medical launches HelixFlex TPE Tubing for India
Freudenberg Medical launches HelixFlex TPE Tubing for India

By IPP Bureau - December 01, 2022

TPE tubing is ideal for pharmaceutical bioprocessing applications because it can be welded to existing tubing lines, and heat-sealed to allow for easy, fast, and safe fluid transport in biopharma processes

SRL Diagnostics launches laboratory in Shimla
SRL Diagnostics launches laboratory in Shimla

By IPP Bureau - December 01, 2022

The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests

WuXi STA launches parenteral formulation manufacturing line at Wuxi
WuXi STA launches parenteral formulation manufacturing line at Wuxi

By IPP Bureau - December 01, 2022

This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units

JB Pharma gets USFDA approval for its generic Venlafaxine Extended-Release Tablets
JB Pharma gets USFDA approval for its generic Venlafaxine Extended-Release Tablets

By IPP Bureau - December 01, 2022

This product is based on Osmotic Controlled Release Oral Delivery System technology

Botanical Solution and Croda Pharma inks agreement to accelerate production for GMP QS-21
Botanical Solution and Croda Pharma inks agreement to accelerate production for GMP QS-21

By IPP Bureau - December 01, 2022

QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.

Akums partners with Leiutis and Biophore for developing products for multiple therapies
Akums partners with Leiutis and Biophore for developing products for multiple therapies

By IPP Bureau - December 01, 2022

The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas

Lonza collaborates with AbTis to extend Bioconjugation capabilities
Lonza collaborates with AbTis to extend Bioconjugation capabilities

By IPP Bureau - November 30, 2022

Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox

Cipla launches Leuprolide Acetate Injection Depot ( (22.5 mg)
Cipla launches Leuprolide Acetate Injection Depot ( (22.5 mg)

By IPP Bureau - November 30, 2022

Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.

Briefs: Lupin and GMM Pfaudler
Briefs: Lupin and GMM Pfaudler

By IPP Bureau - November 30, 2022

The joint venture will help both the parties to further develop the high-margin service business

Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business

By IPP Bureau - November 30, 2022

To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan

CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology
CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology

By IPP Bureau - November 30, 2022

South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe

Zydus enters into BTA for purchase from Watson Pharma
Zydus enters into BTA for purchase from Watson Pharma

By IPP Bureau - November 30, 2022

The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.

Gland Pharma to buy French pharma company Cenexi
Gland Pharma to buy French pharma company Cenexi

By IPP Bureau - November 30, 2022

Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group

AstraZeneca’s Dapagliflozin receives CDSCO approval
AstraZeneca’s Dapagliflozin receives CDSCO approval

By IPP Bureau - November 30, 2022

Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD

Latest Stories

Interviews

Packaging